Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 14, 2025, covering a share repurchase executed on March 13, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme under a non-discretionary agreement entered into on February 24, 2025.
Key Financial Metrics
- Shares Purchased (March 13, 2025): 755,000 ordinary shares.
- Price Range: Lowest price paid was 1,488.50 GBp; highest price paid was 1,507.50 GBp.
- Volume-Weighted Average Price (VWAP): 1,499.80 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: 178,841,345 ordinary shares (post-transaction).
- Shares in Issue (excluding Treasury): 4,136,347,996 ordinary shares.
- Total Voting Rights: 4,136,347,996.
Material Changes
Since the commencement of the current buyback agreement on February 24, 2025, GSK has purchased an aggregate of 9,771,042 ordinary shares. The March 13 transaction represents the latest execution within this programme. The filing does not provide comparative financial data (revenue, profit, cash flow) as it is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the Risk Factors section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F. The purchased shares are held as Treasury shares.
Investor Verification Checklist
- Verify the total number of shares purchased under the current buyback programme (9,771,042 since Feb 24, 2025).
- Confirm the updated count of Treasury shares (178,841,345) and shares in issue (4,136,347,996) for voting rights calculations.
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors associated with forward-looking statements.
- Note that the filing does not disclose revenue, profit, or debt metrics; refer to the most recent Form 20-F or quarterly earnings release for those figures.